Overview

Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
To investigate the curative effect between Pemetrexed/Cisplatin and Pemetrexed/Cisplatin intercalating Gefitinib Treating EGFR Wild NSCLC
Phase:
Phase 2
Details
Lead Sponsor:
Guangzhou Medical University
Treatments:
Cisplatin
Gefitinib
Pemetrexed